Explore evidence

38 %Among 65 severe morbidity episodes, tuberculosis accounted for 25 episodes (38%).

Côte d'Ivoiretuberculosepublished 2007AIDS (London, England)europe_pmcdocument of 9 observations

6.7 %Among 344 HIV-infected pregnant women who conceived on antiretroviral therapy, the overall proportion of stillborn was 6.7%.

Côte d'IvoireVIH/sidaobserved 2003–2009published 2011Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 9 observationsDOI 10.1097/qai.0b013e3181ff04e6

365 daysAntibody responses were observed until Day 365.

Côte d'Ivoiremaladie à virus Ebolapublished 2021PLoS medicineeurope_pmcdocument of 6 observationsDOI 10.1371/journal.pmed.1003813

25.1 %Among individuals with LLIN possession, malaria prevalence was 25.1%.

Côte d'IvoirepaludismeHAL · Unilimdocument of 122 observations

0 %Plasmodium malariae accounted for 0.00% of 2246 identified Plasmodium species.

Côte d'IvoirepaludismeHAL · Unilimdocument of 122 observations

100 %Among participants who slept under an LLIN the night before the survey, infection prevalence was 100.0%.

Côte d'IvoirepaludismeHAL · Unilimdocument of 122 observations

85.4 %Between 2003 and 2005, Plasmodium parasite prevalence ranged from 85.4% to 100% in six villages in northern Côte d’Ivoire.

Côte d'Ivoirepaludismeobserved 2003–2005HAL · Unilimdocument of 122 observations

35.3 %Thirty months after ART initiation, patients in the deferred group had a higher rate of virological failure (35.3% versus 29.9%).

Côte d'IvoireVIH/sidapublished 2021The Journal of antimicrobial chemotherapyeurope_pmcdocument of 8 observations

50 copies/mm3Virologic failure was defined as viral load > 50 copies/mm³.

Côte d'IvoireVIH/sidapublished 2025PloS oneeurope_pmcdocument of 12 observations

2,409 patientsAmong 2409 sickle cell disease patients in the CADRE cohort from Ivory Coast, Cameroon, and Mali, 1751 had the SS-Sβ0 phenotype and 658 had the SC-Sβ+ phenotype.

Cameroun · Côte d'Ivoire · Malidrépanocytosepublished 2015BloodOpenAlexdocument of 16 observations

5.2 yearsThe interquartile range of follow-up duration was 5.2–6.3 years.

Côte d'IvoireVIH/sidapublished 2022HIV medicineeurope_pmcdocument of 6 observations

1.31 hazard_ratioPatients aged 50–59 years had an increased risk of death in the first 36 months on ART with an adjusted hazard ratio of 1.31.

Côte d'IvoireVIH/sidapublished 2018HIV/AIDS (Auckland, N.Z.)europe_pmcdocument of 7 observations

93.5 %The symptomatology of cryptococcal meningitis was subacute in 93.5% of cases.

Côte d'Ivoireméningite cryptococciqueobserved 2008 to 2011published 2017Journal de mycologie medicaleeurope_pmcdocument of 11 observations

6.5 %Two (6.5%) HIV-2 patients switched to a PI-based regimen.

Côte d'IvoireVIH/sidapublished 2020PloS oneeurope_pmcdocument of 13 observationsDOI 10.1371/journal.pone.0236642

2.42 %In Bouaké, symptomatic cases prevalence recorded in August 2016 was 2.42%.

Côte d'Ivoirepaludismeobserved August 2016HAL · Unilimdocument of 122 observations

0.9 sensitivityqHBsAg levels ≤ 100 IU/mL at month 12 had sensitivity of 0.90 and specificity of 1.00 for predicting HBsAg seroclearance.

Côte d'Ivoirehépatite Bobserved month 12published 2016Journal of gastroenterology and hepatologyeurope_pmcdocument of 11 observationsDOI 10.1111/jgh.13156

28.8 %Twelve S-gene MUPIQHs were identified among 21 of 73 HIV-HBV co-infected patients from Côte d'Ivoire, representing 28.8%.

Côte d'Ivoirehépatite Bpublished 2019Liver international : official journal of the International Association for the Study of teurope_pmcdocument of 4 observationsDOI 10.1111/liv.13975

3.7 yearsMean time on failed first-line antiretroviral therapy was 3.7 years for the standard of care.

Côte d'IvoireVIH/sidapublished 2016Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument of 5 observations

2.09 hazard_ratioIn multivariate Cox regression analysis, HIV-1 DNA levels ≥3 log10 copies/million PBMC were strongly associated with mortality (adjusted hazard ratio = 2.09, 95% CI 1.24–3.52, p = 0.005).

Côte d'IvoireVIH/sidapublished 2020EBioMedicineeurope_pmcdocument of 7 observations

10.8 %Of 457 participants included in this study, 39 (10.8%) had cavitation on chest X-ray.

Côte d'Ivoiretuberculosepublished 2025BMC infectious diseaseseurope_pmcdocument of 9 observations

86.9 %Prevalence of P. falciparum infection in the LLIN group was 86.9% (2886/3321) post-intervention.

Côte d'IvoirepaludismeHAL · Unilimdocument of 54 observations

0.61 hazard_ratio6 months of isoniazid preventive therapy reduced all-cause mortality with a hazard ratio of 0.61 (95% CI 0.39 to 0.94) after adjustment for ART strategy, baseline CD4 cell count, and other key characteristics in HIV-infected adults in Côte d'Ivoire.

Côte d'IvoireVIH/sidapublished 2017The Lancet. Global healtheurope_pmcdocument of 6 observations

41 %For children living with HIV, bacterial infections were the leading cause of hospital admission, accounting for 41% of admissions.

Côte d'Ivoirebacterial infectionspublished 2015The lancet. HIVeurope_pmcdocument of 8 observations

10 %Among ART-naive HIV-1-infected adults in Côte d'Ivoire, 10% had occult HBV infection.

Côte d'Ivoirehépatite B · VIH/sidapublished 2010Antiviral therapyeurope_pmcdocument of 7 observations

5 %Anopheles funestus group constituted 5% of malaria vectors in Korhogo health district, northern Côte d’Ivoire.

Côte d'Ivoirepaludismeobserved 1990s–2000sHAL · Unilimdocument of 122 observations